MPS Data Center

Commercialization of the BioSystics-AP™, a web-based resource to accelerate the development, validation, and application of advanced, in vitro, human tissue and disease models.

The UPDDI was one of the three Tissue Chip Testing Centers (TCTCs) funded by the National Center for Advancing Translational Sciences (NCATS) to validate tissue chips for drug efficacy and toxicity testing. As the Microphysiology Systems Data Center we supported the informatics needs of this initiative by extending our Microphysiology Systems Database (MPS-Db) to capture and analyze experimental data generated on diverse organ models by Dr. Ivan Rusyn’s team at Texas A&M University and Dr. Murat Cirit’s team at Javelin Biotech. We have rebranded the MPS-Db to the BioSystics Analytics Platform (BioSystics-AP) and established BioSystics, Inc. to commercialize the BioSystics-AP and make it a self-sustainable resource for the MPS community.  The BioSystics-AP captures and organizes all experimental parameters regarding cell types, drugs tested in the devices so that they may be easily accessed, tracked and used to characterize drug responses in the experimental model. We have developed and implemented tools to evaluate the performance of the tissue chips using known drugs, assessing the reproducibility of the experimental models, and predict pharmacokinetic parameters of new compounds. We are developing computational tools to assess the concordance of MPS experimental model data with clinical endpoints to enable prediction of human organ efficacy and toxicity of new compounds. The Center’s approach exploits University of Pittsburgh’s strengths in drug discovery science, informatics, and database development.

Click here and include “Models” in the Additional Gift Instructions to support developments at the UPDDI of advanced, in vitro, human tissue and disease models in research, drug development, and the clinic.